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Despite the unprecedented success of vaccines in the 20th century in eradicating small-pox and 
drastically controlling the spread of diseases like polio, we are presently experiencing a public crisis 
of confidence in vaccination programs. The global decline in vaccination coverage has compromised 
the effectiveness of vaccines, which function on the basis of a combination of individual protection 
and the concept of “herd immunity.” Herd or “group immunity” is attained if a high vaccine coverage 
(around 95% of the population for certain vaccines) is reached and maintained. This limits the spread 
of infectious diseases, ensuring the protection of vaccinated persons as well as those who do not 
develop immunity after vaccination or remain vulnerable due to certain underlying medical conditions. 
With reducing rates of immunization, herd immunity is compromised leading to drastic consequences 
as seen in recent measles outbreaks that have resulted in 140,000 deaths in 2018.1 Since then the 
situation has worsened, as of mid-November 2019 there have been 413,000 cases reported globally, 
marking a three-fold increase as compared to 2018.2 Alongside present outbreaks of the “novel corona 
virus”, limiting the spread of dangerous vaccine preventable diseases represents a quintessential 
problem of our times.  
A curious aspect of vaccine hesitancy is that the revolutionary effectiveness of mass vaccination 
programs paradoxically results in an eventual reduction in immunization rates making “vaccines a 
victim of their own success”.3 This point is best understood in stages.  In the first stage, the prevalence 
and threat of vaccine-preventable infectious diseases impinges on parents leading them to vaccinate 
their children. The administered vaccines are immensely successful in reducing the spread and 
prevalence of vaccine-preventable diseases. This leads to the second stage where these diseases lose 
their importance in the collective imagination and sections of the public turn their attention to: a) the 
 
1 World Health Organization. More than 140,000 die from measles as cases surge worldwide, (2019a, December 5). 
Retrieved from https://www.who.int/news-room/detail/05-12-2019-more-than-140-000-die-from-measles-as-cases-surge-
worldwide 
2 ibid  
3 Robert T. Chen, and B. Hibbs, "Vaccine Safety: Current and Future Challenges." Pediatric Annals 27, no. 7 (1998); Ricki 
Lewis. "Vaccines: Victims of Their Own Success? Why the Most Effective Public Health Intervention Evokes a Mixed 
Response from the Public." The Scientist 18, no. 14 (2004); Heidi J Larson, Louis Z. Cooper, Juhani Eskola, Samuel L. 
Katz, and Scott Ratzan. "New Decade of Vaccines 5 Addressing the Vaccine Confidence Gap." Lancet 378, no. 9790 
(2011). 
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possibility of adverse side effects from vaccinating,4 b) religious objections to vaccinating,5 c) 
opposition to conventional medicine coupled with the perceived need for children to develop their 
“natural immunity”,6 and d) objections to state mandated vaccinations.7 Despite the moderate success 
of dialogue-based interventions to increase awareness and partial success of non-financial incentive 
based interventions as well as reminder/recall based interventions in certain parts of the world, vaccine 
hesitancy persists as one of the major threats to global health today.8  
Among the many reasons driving vaccine hesitancy, this paper will focus on parental concerns 
with adverse side effects of early-childhood vaccinations in high income countries. The concern with 
side-effects post-vaccination varies vastly with social and cultural contexts. This paper limits its 
analysis to high income countries because the concern with adverse side effects in this context allows 
for an evaluation of bio-medical evidence supporting vaccines, which is the focus of this paper.    
1. Vaccine Hesitancy from the Parental Perspective 
To understand a hesitant parents’ perspective, I return to the previous discussion of vaccines becoming 
a “victim of their own success”. The application of mass vaccination programs led to the drastic decline 
in the threat and prevalence of infectious vaccine-preventable diseases. Parents are therefore not 
confronted with cases of the disease infecting other children around them. As a result, the prospect of 
contracting the disease is no longer experienced as a real possibility. Additionally, the case to convince 
hesitant parents to vaccinate is not helped by the increased prevalence of misinformation about what 
vaccines could do to their children. This perfectly captures the controversy surrounding the Mumps-
Measles-Rubella (henceforth MMR) vaccine, an early-childhood vaccination falsely linked to autism 
by Andrew Wakefield.9 Despite the retraction of his now infamous paper, following repeated 
 
4 Helen Bedford, and David Elliman, "Concerns about Immunisation. (Education and Debate)." British Medical 
Journal 320, no. 7229 (2000). 
5 Lainie Friedman Ross, and Timothy J. Aspinwall, "Religious Exemptions to the Immunization Statutes: Balancing Public 
Health and Religious Freedom." Journal of Law, Medicine & Ethics 25, no. 2-3 (1997). 
6 Matthew Browne, Patricia Thomson, Matthew Justus Rockloff, and Gordon Pennycook, "Going against the Herd: 
Psychological and Cultural Factors Underlying the 'Vaccination Confidence Gap'." 10, no. 9 (2015): E0132562. 
7 R Prislin, J A Dyer, C H Blakely, and C D Johnson, "Immunization Status and Sociodemographic Characteristics: The 
Mediating Role of Beliefs, Attitudes, and Perceived Control." American Journal of Public Health 88, no. 12 (1998). 
8 World Health Organization. Top ten threats to global health in 2019, 2019b. Retrieved from 
https://www.who.int/emergencies/ten-threats-to-global-health-in-2019 
9 Andrew Wakefield, Anthony Murch, Casson Linnell, Malik Berelowitz, Dhillon Thomson, Harvey Valentine, Davies, 
and Walker-Smith, "Ileal-lymphoid-nodular Hyperplasia, Non-specific Colitis, and Pervasive Developmental Disorder in 
Children." Lancet 351, no. 9103 (1998). 
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refutations and evidence of fraudulent research,10 Wakefield’s claims continue to damage the 
reputation of early-childhood vaccinations as a whole and plays a major role in contemporary vaccine 
hesitancy and the parental concern with adverse side effects.11 This is further jeopardized by the 
increased commercialization of pharmaceutical research making vaccines a lucrative business, 
enabling further parental scepticism of the intentions underlying mass vaccination programs. 
When bio-medical experts defend the safety and effectiveness of vaccines, they tend to rely on 
population level analysis. These analysis point to the fact that vaccines are generally safe and that 
adverse side effects occur on the rarest of rare occasions. The rarity of adverse side effects is contrasted 
with the increased likelihood and severity of getting the disease if the child was not vaccinated. Given 
this choice, experts argue that the safest and most reasonable course of action is for parents to vaccinate 
their children. Consider Health Canada’s promotion leaflet:  
Misconception: Vaccines are not safe. 
 
The Facts: Vaccines are among the safest medical products available. Prior to approval 
they are extensively tested and they continue to undergo rigorous ongoing evaluations 
of their safety when on the market. Serious side effects such as severe allergic reactions 
are very rare. On the other hand, the diseases that vaccines fight present serious threats. 
Diseases like polio, diphtheria, measles, and pertussis (whooping cough) can lead to 
paralysis, pneumonia, choking, brain damage, heart problems, and even death. The 
dangers of vaccine preventable diseases are many times greater than the risk of a 
serious adverse reaction to the vaccine.12 
 
In other words, bio-medical experts argue that the risks associated with contracting vaccine-
preventable diseases is far greater than the rare possibility of an adverse side-effect post vaccination. 
However, qualitative analysis shows that hesitant parents do not evaluate the choice of 
vaccinating in this way. With vaccines becoming a “victim of their own success” the diseases that 
experts warn against are no longer prevalent or threatening to parents. For this reason, bio-medical 
claims regarding the grave risks of contracting vaccine preventable diseases would not have the desired 
impact. Additionally, the claim that adverse side effects are extremely rare does not encourage parents 
to vaccinate. Unlike bio-medical experts, parents do not evaluate the safety of vaccines at the 
 
10 Robert T Chen, and Frank Destefano, "Vaccine Adverse Events: Causal or Coincidental?" The Lancet 351, no. 9103 
(1998): 611-12; Michael Fitzpatrick. "MMR: Risk, Choice, Chance." British Medical Bulletin 69, no. 1 (2004): 143-53; 
Paul A Offit. Autism's false prophets : bad science, risky medicine, and the search for a cure. (New York: Columbia 
University Press, 2010). 
11 Mark A Largent, Vaccine : the debate in modern America, (Baltimore: Johns Hopkins University Press, 2012). 
12 Government of Canada, Health Canada. 2011. Misconceptions about Vaccine Safety. Ottawa: Government of Canada., 
2011. Retrieved from: http://healthycanadians.gc.ca/health-sante/medicinemedicament/misconception-eng.php; also cited 
in Maya J Goldenberg, "Public Misunderstanding of Science? Reframing the Problem of Vaccine Hesitancy."  Perspectives 
on Science 24, no. 5 (2016); 566.  
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population level, but in relation to their child. Consequently, hesitant parents are worried rather than 
reassured by expert claims that adverse side effects are rare as any risk means that their child could be 
affected.13 In other words, hesitant parents are not concerned with the general safety of vaccines but if 
vaccines are safe for their particular child. Or, as Maya Goldenberg notes, in the case of the previously 
discussed controversy surrounding the MMR vaccine, hesitant parents “expressed vaccine fear that 
would not be relieved by reassurances that MMR was safe for the general public. They wanted to 
know: ‘Is MMR safe for my child?’”14   
This personal framing of the risk of vaccinating is grounded upon the parental concern with the 
uniqueness of their child based on her particular family history in relation to specific side effects, 
allergies, and auto-immune problems. Some parents were also seen to consider the child’s birthing 
time, maturity, sleep patterns, and overall behaviour. These reasons were taken to be significant when 
a parent evaluates if their child was more susceptible to an adverse side effect from vaccinating than 
others. Some parents like David Trowther, as instance of “citizen science”, have even explored the 
possibility of identifying which sub-set of children would respond badly to vaccinations by studying 
the particular family histories and genetic make-up of children that experienced adverse reactions.15 
However, Trowther’s research suffers from sampling and reporting bias.  
There have been several official responses to hesitant parents and their personal framing of the 
risk of vaccinating. Bio-medical scholarship has focused on i) the impact of misinformation campaigns 
by anti-vax organizations, ii) the public misunderstanding of bio-medical research, and iii) the distrust 
of bio-medical institutions, among others. While these reasons definitely impact a hesitant parent’s 
reception of the scientific evidence defending vaccine safety, they only focus on the distorting factors 
that dissuade parents from vaccinating. It is also important to ask if bio-medical evidence or the manner 
in which it is used to defend vaccines contributes to parents being hesitant to vaccinate. In particular, 
this paper examines why bio-medical experts continue to use population level analysis when dealing 
with parents who are not concerned with the general safety of vaccines. Or put differently, this paper 
analyses why bio-medical institutions have not been able to marshal scientific evidence in a manner 
that effectively speaks to parents and their concern with individual cases of adverse side-effects post-
vaccination. To understand why this is the case, the next section will focus on the distinguishing 
features of bio-medical evidence.  
 
13 Pru Hobson‐West, "‘Trusting Blindly Can Be the Biggest Risk of All’: Organised Resistance to Childhood Vaccination 
in the UK." Sociology of Health & Illness 29, no. 2 (2007); Goldenberg, Public Misunderstanding of Science?, 563-567. 
14 Goldenberg, Public Misunderstanding of Science?, 564; emphasis added.  
15David Trowther. MMR and Acquired Autism (Autistic Enterocolitis): A Briefing Note, (2002) 
http://www.whale.to/a/thrower.html 
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2. Evidence Based Medicine and the Hierarchy of Evidence   
The dominant operative framework in contemporary medical practice is referred to as Evidence Based 
Medicine (henceforth: EBM). The standard definition of EBM is ‘‘the conscientious, explicit, and 
judicious use of current best evidence in making decisions about the care of individual patients’’.16 
Taken at face value this definition has a ring of obviousness. In principle, we would all like medical 
professionals and institutions to follow the best evidence when making clinical decisions. However, 
this obviousness betrays the fact that EBM functions as an epistemological framework that examines 
the validity of different forms of bio-medical knowledge.17 Additionally, EBM extends its 
epistemological concerns to clinical decision making and the practical concerns underlying bio-
medical practice.18 EBM has been immensely successful in moving beyond many enduring medical 
controversies, avoiding a number of the pitfalls in medical practice by preventing the misapplication 
of new technologies and therapies, all the while encouraging critical thinking and scientific scepticism 
within the bio-medical community. However, with such success the validity of the EBM 
epistemological framework has been taken for granted, immediately applied to clinical practice and 
the bio-medical community has been reluctant in acknowledging its limitations.19  
What distinguishes EBM as an epistemological framework is its constitution of a hierarchy of 
evidence. The hierarchy is as follows:  
1. Systematic Review and Meta-Analysis 
2. Randomized Controlled Trials 
3. Cohort Studies  
4. Case Controlled Studies 
5. Cross Sectional surveys 
6. Case Reports 
7. Expert Opinion 
8. Anecdotal20  
The hierarchy functions as an evolutionary continuum “moving from simple observational methods at 
the bottom through to increasingly sophisticated and statistically refined methodologies”.21 This 
 
16 David L Sackett, William M C Rosenberg, J A Muir Gray, R Brian Haynes, and W Scott Richardson. "Evidence Based 
Medicine: What It Is and What It Isn't." BMJ 312, no. 7023 (1996): 71. 
17 Mark R Tonelli, "The Philosophical Limits of Evidence-based Medicine." Academic Medicine 73, no. 12 (1998); 1235.  
18 ibid.  
19 ibid, 1235; 1237.  
20 School of Health and Related Research, University of Sheffield. “Hierarchy of Evidence” in Arguing About Science, Ed. 
by Alexander Bird and James Ladyman, 540-542 (New York: Routledge, 2013), 541. 
21 Ibid, 540.  
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represents a focal point of the EBM epistemological framework: statistically refined knowledge is 
privileged over observational insights. The reasoning being that observational methods tend to be 
unsystematic and experiential in character. For instance, “case reports” are often based on a single 
patient and therefore its validity is limited to the particular physiological make up, preferences, and 
values of that patient. Similarly, “expert opinion” or clinical expertise is gained over years of 
experience and is therefore unsystematic given that it varies with different institutions and personal 
make-up of the clinician. In specific instances, the experts also arrive at a consensus on the basis of 
their divergent experiences. Lastly, “anecdotal” at the bottom of the hierarchy designates knowledge 
derived from personal intuition rather than facts or research.  
Despite their unsystematic and varying experiential character, observational methodologies can 
get things right. EBM places them at the lower end of the hierarchy because, as per its understanding, 
these methods only get things right incidentally. An often-quoted example being James Lind’s famous 
work on scurvy.22 During the 18th century, scurvy killed more British sailors than enemy combatants. 
As a naval surgeon aboard the HMS Salisbury, Lind compared several suggested cures and eventually 
comes to the conclusion that “oranges and lemons were the most effective remedies for this distemper 
at sea”.23 Lind’s findings overlooked that fact that it was vitamin C in oranges and lemons that cured 
scurvy; an insight Lind was not privy to as vitamins would not be isolated and described for another 
150 years. While Lind was right and his proposed treatment was highly effective in helping sailors 
protect themselves against scurvy, it was only incidentally correct as the particular prognostic factor 
that achieved the stated therapeutic end was not accurately identified.  
What requires emphasis is that EBM’s concern with observational methods is not directed at 
the benefit they provide patients. Lind’s treatment was highly successful and immediately 
implemented by the British navy bringing much relief to English sailors. What concerns EBM is that 
Lind did not isolate and identify the particular causal factor that protected sailors from scurvy. In 
other words, EBM is concerned with the methodology and manner in which Lind’s observational 
insights are attained. This points to a gap between EBM’s conception of good quality clinical research 
and the goals of medical practice. As Mark Tonelli notes, the primary goal of medical practice “for its 
entire history … [has] been defined in terms of benefit to the individual patient” represented in the 
 
22 Before proceeding it is important to stress that my reference to Lind is for explanatory purposes alone and I do not aim 
to make a theoretical point about Lind himself in the following paragraph. Especially because Lind’s work pre-dates the 
institutionalization of EBM. Despite this, Lind’s research on scurvy has been used in EBM literature to point to the 
limitations of even successful observational theories. My reference to Lind’s work follows in this vein. For more see, 
School of Health and Related Research, University of Sheffield, Hierarchy of Evidence, 540.  
23 James Lind, A Treatise on the Scurvy: In Three Parts, Containing an Inquiry Into the Nature, Causes, an Cure, of that 
Disease, Together with a Critical and Chronological View of what Has Been Published on the Subject. 1772; Retrieved 
from: https://archive.org/details/b30511902; 493. 
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“attempt to improve or maintain the health of an individual”.24 EBM on the other hand is oriented 
towards the methodology and process through which bio-medical research comes to its conclusions. 
While the concern with research process and methodology would effectively contribute to beneficial 
treatment of any and every patient, therefore patients as such. This orientation is rather abstract and 
not the same as the immediate pragmatic orientation of medical practice towards a particular individual 
patient present with specific symptoms in the clinical setting. This gap, although subtle, can lead to a 
conflict between EBM’s focus on methodology and the betterment of the particular individual patient. 
To better understand when such a gap could arise and lead to a conflict, I shall briefly introduce 
methodologies on the higher end of the EBM hierarchy.  
3. Randomized Controlled Trials and its Limitations  
Randomized Controlled Trials (henceforth: RCTs) are considered to be the gold standard among the 
methodologies in the EBM hierarchy. It occupies the second highest position, with “systematic review 
and meta-analysis” which occupies the first position being a synthesis of evidence attained from 
numerous RCTs. An RCT is undertaken to test a specific drug, treatment, or intervention. It entails 
randomly assigning participants to a trial into two or more groups. One group, the experimental group, 
receives the treatment that is being tested. The other group, the comparison or control group, receives 
a placebo or no intervention at all. The researchers then follow up to see how effective the treatment 
is by comparing patients in the experimental group with those in the control group. This method is the 
considered to be the benchmark by the bio-medical community because, among other reasons, it 
attempts to systematically avoid the post hoc ergo propter fallacy.25 This fallacy refers to the mistaken 
claim that if event Y followed event X, then the former must have been caused by the latter. However, 
the causal link between the two events has not been established. Event Y is merely following Event X. 
To attain evidence for a causal link, there needs to be an experiment that controls for the other 
associated factors that could also be at play in the transition from event X to event Y. This entails 
putting out of play the other associated factors that could be playing a causal role to examine the 
relationship between event X and Y. Such an examination can go either of two ways: event X and Y 
might show as relating to each other in a causal manner or not. In the latter case, the experiment would 
then point towards the other associated factors playing a causal role or a combination of event X and 
said associated factors playing such a role.  
 
24 Tonelli, Philosophical Limits of EBM, 1236. 
25 John Worrall, “What Evidence in Evidence Based Medicine”, in Arguing About Science, Ed. by Alexander Bird and 
James Ladyman. New York: Routledge, 2013; 546. 
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While there is always the possibility of an unknown factor continuing to play a role despite 
attempts to control the experiment, randomization is taken to be the most effective approach to limit 
this possibility for two reasons. First, if patients in the experimental group were healthier or more 
likely to react positively to the treatment because of some factor that pertains to their physical makeup, 
then the trial would be a success as the results would show those in the experimental group doing better 
than the control group. Randomization checks this tendency by limiting the extent to which such a 
scenario would take place. Through random allocation, the tendency to group patients of a similar 
makeup in one group is lessened. However, this claim must not be understood in the strong sense 
because there always exists the possibility that a random allocation might lead to a highly skewed 
division between experimental and control groups. Instead, most proponents of randomization argue 
in a probabilistic sense. Sheila Gore, for example, claims that randomization is an “insurance, in the 
long run, against accidental bias” that might inadvertently skew the allocation of patients.26 Second, 
randomization significantly checks selection bias on part of those setting up the trial.27 If clinicians 
were to decide how patients were to be allocated, the trial would only be single blind as those setting 
up the trail would still be influencing proceedings. Randomization avoids selection bias and makes the 
trial double blind by severely limiting the extent to which those setting up the trial can influence the 
allocation of patients.   
 Both reasons are attempts to control the trial for associated factors that could be playing a 
causal role. This enables RCTs to focus on the relationship between the treatment being tested and the 
effect it has on the patients. As noted previously, unlike medical practice, EBM is not directly 
concerned with a particular individual patient with specific symptoms. Instead, EBM’s focus is the 
bio-medical research process and the methodology it uses to improve/benefit the health of any and 
every patient, i.e. patients as such. To simplify, there are two gaps. The first, between medical 
practice’s orientation towards a particular individual patient and EBM’s orientation towards a 
generalized conception of the patient. The second, between medical practice’s focus on benefitting the 
individual patient and EBM’s concern for maintain the quality of the research process and 
methodology; a concern that does not directly co-relate to benefitting the individual patient. For the 





26 Sheila Gore, "Assessing Clinical Trials--why Randomise?" British Medical Journal (Clinical Research Ed.) 282, no. 
6280 (1981); 1958.  
27 Worrall, What Evidence in EBM, 548. 
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These two gaps present themselves in the case of RCTs. It has been noted that randomization is only 
able to control for quantifiable differences between patients. Important non-quantifiable aspects 
characterizing the individual patient like pain tend to be overlooked. While EBM has attempted to 
rectify this limitation by quantifying pain using “visual analog or ordinal rating scales”, these efforts 
further emphasize that EBM is only willing the deal with quantifiable differences by converting pain 
into measurable parameters.28 In other words, when confronted with non-quantifiable differences 
between individual patients, the EBM practitioner could either re-affirm RCTs preference for 
quantifiable parameters or re-orient RCTs by triangulating its findings with other methodologies. In 
keeping with Gap 1, EBM is less concerned with the particularities of the individual patient and more 
concerned with the generalized patient as such. In keeping with gap 2, EBM is more concerned with 
the research process and methodology than with benefitting the individual patient. For these reasons, 
and as seen in the case of pain, the EBM practitioner re-affirms EBM’s preference for quantifiable 
parameters at the cost of the non-quantifiable concerns of the individual patient. As a result, EBM’s 
concern towards benefitting the generalized patient by focusing on research process and methodology 
conflicts with a concern for the individual patient.    
This point is further evidenced by the fact that non-quantifiable individual differences can be 
identified with the help of clinical expertise, which EBM places near the bottom of its hierarchy owing 
to its unsystematic and experiential character. Moreover, as seen with the second reason for RCTs, 
randomization curbs the involvement of clinicians to avoid selection bias. To put it in terms of the two 
gaps, EBM’s orientation towards the generalized patient (gap 1) and focus on maintain the quality of 
the research process and methodology (gap 2) entails that it will not re-orient its research process or 
methodology to incorporate clinical expertise to better deal with non-quantifiable particularities of the 
individual patient. The point being emphasised is not that the problems with selection bias need to be 
overlooked so that clinicians can identify important non-quantifiable differences between patients. 
Instead, I argue that the epistemological standpoint that underlies EBM is unable to make a distinction 
between the right and wrong kind of clinical involvement in patient allocation in RCTs. In other words, 
 
28 Tonelli, Philosophical Limits of EBM, 1236. 
Tarun Kattumana                                         10 
 
when faced with the prospect of tempering its high evaluation of systematic and statistical 
methodologies to incorporate unsystematic and experiential forms of bio-medical knowledge like 
expert opinion to more adequately deal with individual patients, EBM maintains its hierarchy of 
evidence and privileging of systematic and statistical methodologies over unsystematic and intuition 
based bio-medical forms of knowing. This points to the underlying positivist tendencies of EBM’s 
epistemological framework.  
 Goldenberg notes that EBM holds on to an “antiquated understanding of evidence as ‘facts’ 
about the world in the assumption that scientific beliefs stand or fall in light of the evidence”.29 This 
is based on the positivist understanding of the process of scientific inquiry where: 
… any bias that enters scientific inquiry in the context of discovery is eradicated in the 
purifying process of the context of justification. The evidence left standing after scientific 
inquiry is assumed to be ‘facts’ about the world and therefore warrants the title scientific 
evidence.30   
It is in this respect that EBM has been attractive to many in bio-medicine. It rationalizes the complex 
social process through which scientific evidence is attained, where this rationalization follows a 
“positivistic elimination of culture, contexts, and the subjects of knowledge production from 
consideration” thereby portraying the use of evidence as a value free and “neutral technical” measure.31 
This is seen in EBM’s re-affirming of the hierarchy of evidence where contextual and subjective bio-
medical knowledge is placed at the lower end while methodologies that eschewed unsystematic 
intuition and maintained statistical sophistication were placed higher up.  
When faced with the prospect of reorienting its research procedures to incorporate non-
quantifiable differences between patients, EBM opts to maintain its research procedures for the sake 
of scientific rigour. Here scientific rigour has a positivist connotation where the subjective aspects of 
knowledge production are eschewed for research output that is value free and neutral. This is evidenced 
by EBM’s hierarchy of evidence that privileges RCTs, even though this form of experimentation 
struggles to incorporate a patient’s particularity, and downgrades expert opinion that could adequately 
deal with the particular patient. This rigidity on EBM’s part points towards a conflict between its 
concern with maintaining its conception of the quality of the research process and methodology and 
adequately dealing with particularities/non-quantifiable differences that characterise the individual 
 
29 Maya J Goldenberg, "On Evidence and Evidence-based Medicine: Lessons from the Philosophy of Science." Social 
Science & Medicine 62, no. 11 (2006); 2622.  
30 ibid, 2623. 
31 ibid, 2622. 
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patient. This conflict is explicitly seen in the case of vaccine hesitancy and how bio-medical experts 
cannot adequately deal with hesitant parents and their personal framing of the risk of vaccinating.  
4. Vaccines and the Reporting of Adverse Side-Effects  
To get approval32 a new vaccine has to go through five phases of rigorous testing that checks for quality 
and safety.33 Despite this, vaccines like any other pharmaceutical product are not risk free. While most 
side effects are minor, serious adverse effects remain a possibility even after the testing phase. For this 
reason, on-going passive surveillance programs are maintained to monitor vaccine safety.34 They 
function as repositories for voluntarily submitted information regarding instances of adverse side 
effects. To encourage reporting of adverse side-effects, the system accepts any report submitted. This 
includes reports submitted by doctors, nurses, patients, pharmacists, or parents. VAERS (Vaccine 
Adverse Event Reporting System) a variant of this system in the United States of America receives 
approximately 30,000 reports a year.35  About 10-15% of these cases describe a serious adverse effect 
such as permanent disability, hospitalization, life-threatening illness, or death.36 The other 85-90% of 
the reports describe mild side-effects such as fever, arm soreness, and crying or mild irritability.37 
While minor side effects can be proven to be caused by the vaccine, it is harder to do so with serious 
 
32 Before proceeding it is important to note that public health recommendations for vaccines have sometimes been 
contradicted by EBM findings. In response to scepticism against the MMR vaccine, the Institute for Medicine and the 
American Academy of Paediatrics has defended the safety of this vaccine. However, some EBM findings that contradicted 
these claims and concluded that the “design and reporting of safety outcomes in MMR vaccine studies, both pre- and post-
marketing, are largely inadequate”. For more see, Vittorio G. Demicheli, Alessandro Rivetti, Maria Grazia Debalini, and 
Carlo Di Pietrantonj, "Vaccines for Measles, Mumps and Rubella in Children." Cochrane Database of Systematic Reviews 
(Online) 2 (2012); also quoted in Robert M Jacobson, Paul V Targonski, and Gregory A Poland, "Why Is Evidence-based 
Medicine so Harsh on Vaccines? An Exploration of the Method and Its Natural Biases." Vaccine 25, no. 16 (2007); 3166. 
However, this issue falls outside the ambit of the present research as this paper is limited to an examination of why the bio-
medical evidence cannot convincingly speak to the concerns of hesitant parents.  
33 In phase one, the new vaccine is tested on a limited sample size of healthy people to test for potential adverse side effects 
occurring post-vaccination. This is followed by phase two where research is done on a larger scale to identify the 
appropriate dosage and regiments for the proper administering of the vaccine to different target age groups. Phase three 
sees the use of RCTs that are double blind and placebo controlled in a population with an adequate incidence of the target 
disease. During this phase, statistical considerations determine the ideal sample size to estimate the efficacy of the new 
vaccine. If the new vaccine passes the RCT phase, it is taken to have met the golden standard of testing and attains a 
licensure making it ready to be applied in real world conditions with sample sizes between 10,000 to 90,000 subjects in 
phase four of testing. Lastly, phase five sees local studies conducted to gain licensure in other countries other than the ones 
in which the previous four phases of testing were conducted. For more see, David R. Nalin, "Evidence Based 
Vaccinology." Vaccine 20, no. 11-12 (2002); 1625.  
34 An active surveillance system would follow certain patients to determine what their responses to the vaccine was. As 
opposed to this a passive surveillance system would not follow patients but wait to receive reports of adverse side effects.  




37 Ibid.   
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adverse side effects. At this juncture it is important to consider the disclaimer that the CDC providers 
any user of VAERS: 
While very important in monitoring vaccine safety, VAERS reports alone cannot be used to 
determine if a vaccine caused or contributed to an adverse event or illness. The reports may 
contain information that is incomplete, inaccurate, coincidental, or unverifiable. Most reports 
to VAERS are voluntary, which means they are subject to biases. This creates specific 
limitations on how the data can be used scientifically. Data from VAERS reports should always 
be interpreted with these limitations in mind.38  
In other words, because VAERS accepts any report submitted by anyone, there is no quality check on 
the submission. Some of these reports could be “incomplete, inaccurate, co-incidental or unverifiable”. 
Additionally, most reports are “subject to biases”. For these reasons the CDC asks that any 
interpretation of the VAERS data must keep these limitations in mind.   
The above disclaimer resonates with EBMs concern with the validity of anecdotal claims (last 
position in the hierarchy of evidence) and other observational methods. In particular, it points to its 
attempts to systematically avoid the post hoc ergo propter fallacy. It is not enough to claim that certain 
side-effects temporally followed vaccination. To make a causal claim, the process of vaccinating needs 
to be controlled for other possible causal actors that could be causing the adverse side effect. According 
to Susan Ellenberg and Robert Chen, there are four instances when a serious side effect could be 
causally attributed to the vaccine:  
(a) the event conforms to a specific clinical syndrome whose association with vaccination has 
strong biological plausibility;  
(b) a laboratory result confirms the association; 
(c) the event recurs on re-administration of the vaccine; 
(d) a controlled clinical trial or carefully designed epidemiologic study shows greater risk of 
adverse events among vaccinated than control groups.39  
Ellenberg and Chen go on to note that: 
Because few of the adverse events reported to VAERS meet any of the first three criteria and 
because clinical trials are almost always too small to provide useful information on serious rare 
events, epidemiologic evidence is the basis for assessing causality for most serious adverse 
events that are investigated.40 
Put differently, most reports of adverse side effects do not meet three of the four criteria listed for 
when a serious adverse effect could be attributed to the vaccine. A fourth criteria for evaluating a report 
for adverse side effects through clinical trials still remains. But Ellenberg and Chen claim that the 
 
38CDC, About The Vaccine Adverse Event Reporting System (VAERS). Retrieved from: 
https://wonder.cdc.gov/vaers.html; emphasis added.  
39 Susan Ellenberg, and Robert T. Chen. "The Complicated Task of Monitoring Vaccine Safety." Public Health Reports 
(Washington, D.C: 1974) 112, no. 1 (1997); 15. 
40 Ibid. 
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clinical trials would be “too small to provide useful information on serious rare events”. For this reason, 
“epidemiologic evidence” is taken as the basis for “assessing the causality … [of] adverse events”.   
  
Conclusion: EBM and Vaccine Hesitancy 
The preference for epidemiological data is limiting when it comes to convincing hesitant parents to 
vaccinate. As noted previously, experts tend to rely on population level data to argue for the general 
safety of vaccines. Hesitant parents are however not convinced by epidemiological population level 
studies because such data only argues for the general safety of vaccines by noting that adverse side 
effects are extremely rare. Such claims overlook the point that hesitant parents are not reassured these 
expert claims but are worried as any possibility of risk could mean that their child could be affected.  
Despite this, experts continue to marshal population level data to convince hesitant parents. This is 
evidenced by the bio-medical reaction to the limitations of the VAERS data and reverting to 
epidemiological evidence as seen in the previous section.  
To avoid misunderstanding, it is important to stress that this paper does not criticize bio-medical 
experts for identifying real problems with the reporting of adverse cases in the VAERS data. These 
problems remain a serious obstacle to properly identifying the causal factors that contribute towards 
rare but adverse side effects post-vaccination. Instead, this paper attempts to understand why 
significant sections of the bio-medical community and most pro-vaccine argumentation continues to 
use population level epidemiological data to prove the general safety of vaccines, when the target 
audience of these messages are hesitant parents who are not concerned with general safety but the rare 
instances of adverse side effects.  
I argue that the epistemological framework underlying EBM contributes to the continued reliance 
of the bio-medical community and pro-vaccine advocates on epidemiological population level data. 
This framework bases itself on a hierarchy of evidence that is underpinned by a positivist orientation 
that eschews the culture, contexts, and subjects of knowledge production to attain evidence that is 
purportedly value free and neutral. As a result, EBM’s hierarchy of evidence endorses systematic and 
statistical methodologies while downgrading subjective and experiential forms of bio-medical 
knowledge. While the constitution of this hierarchy and its application to medical practice has seen 
remarkable success, it also important to point to its limitations. With its overarching concern for 
maintaining the quality of the research process and methodology, the practice of EBM tends to 
overlook the particularities and non-quantifiable aspects of individual cases or patients. This is 
particularly the case when EBM practitioners and methodologies are confronted with individual 
instances and attempt to re-affirm the positivist underpinnings of EBM’s epistemological standpoint. 
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As a result, there is a conflict between EBM’s aims to affirm its conception of scientific rigour and 
incorporating the particularities of individual patients/cases.  
This conflict extends to vaccines hesitancy. Hesitant parents are not concerned with the general 
safety of vaccines and so are not persuaded by statistical and population level analysis affirming the 
safety of vaccinating. Instead, they are concerned with the rare instances of adverse side effects that 
might befall their children.  The association of these rare adverse side-effects with vaccines is however 
not provable in terms of EBM research practices and procedures that as previously noted have a 
difficulty incorporating individual instances and particularities of patients/cases. In such cases the 
aforementioned conflict between maintaining a certain understanding of scientific rigour and 
incorporating the particularities and peculiarities of individual patients/cases follows; and EBM 
reaffirms the former at the cost of the latter. Or as in case of VAERS reporting, bio-medical experts 
re-affirm epidemiological evidence to assess the causality of the cases of adverse side-effects reported.  
While further research is required to show how the bio-medical community can effectively speak 
to the hesitant parents concerned with rare but adverse side effects from vaccinating, this paper has 
argued that the present form of the epistemological framework underlying EBM presents an obstacle 
from doing so. 
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